

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5469619

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
NEKTAR THERAPEUTICS	03/29/2019
RECEIVING PARTY DATA	
Name:	TC LENDING, LLC, AS COLLATERAL AGENT
Street Address:	301 COMMERCE STREET
Internal Address:	SUITE 3300
City:	FORT WORTH
State/Country:	TEXAS
Postal Code:	76102
PROPERTY NUMBERS Total: 9	
Property Type	Number
Application Number:	62789924
Application Number:	16243914
Application Number:	16319759
Application Number:	16259732
Application Number:	16266718
Application Number:	16277785
Application Number:	16280741
Application Number:	62818003
Application Number:	62825437
CORRESPONDENCE DATA	
Fax Number:	(415)520-9358
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	atran@nektar.com
Correspondent Name:	NEKTAR THERAPEUTICS
Address Line 1:	455 MISSION BAY BOULEVARD SOUTH
Address Line 2:	SUITE 100
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94158
NAME OF SUBMITTER:	SUSAN T. EVANS

SIGNATURE:	/Susan T. Evans/
DATE SIGNED:	04/11/2019
Total Attachments: 4 source=US Security Grant March 2019 Fully Executed#page1.tif source=US Security Grant March 2019 Fully Executed#page2.tif source=US Security Grant March 2019 Fully Executed#page3.tif source=US Security Grant March 2019 Fully Executed#page4.tif	

GRANT OF SECURITY INTEREST
IN UNITED STATES PATENTS


FOR GOOD AND VALUABLE CONSIDERATION, receipt and sufficiency of which are hereby acknowledged, Nektar Therapeutics, a Delaware corporation (the "Grantor") with principal offices at 455 Mission Bay Blvd South, Suite 100, San Francisco, CA 94158, hereby grants to TC Lending, LLC, as Collateral Agent, with principal offices at 301 Commerce Street, Suite 3300, Fort Worth, TX 76102, (the "Grantee"), a continuing security interest in (i) all of the Grantor's rights, title and interest in, to and under the United States patents (the "Patents") set forth on Schedule A attached hereto, in each case together with (ii) all proceeds (as such term is defined in the Uniform Commercial Code of the State of New York as in effect from time to time) and products of the Patents, and (iii) all causes of action arising prior to or after the date hereof for infringement of any of the Patents or unfair competition regarding the same.

THIS GRANT is made to secure the satisfactory performance and payment of all the Obligations of the Grantor, as such term is defined in the Pledge and Security Agreement among the Grantor, the other Grantors from time to time party thereto and the Grantee, dated as of October 5, 2015 (as amended, modified, restated and/or supplemented from time to time, the "Security Agreement"). Upon the occurrence of the Termination Date (as defined in the Security Agreement), the Grantee shall execute, acknowledge, and deliver to the Grantor an instrument in writing releasing the security interest in the Patents acquired under this Grant.

THIS GRANT has been granted in conjunction with the security interest granted to the Grantee under the Security Agreement. The rights and remedies of the Grantee with respect to the security interest granted herein are as set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

IN WITNESS WHEREOF, the undersigned have executed this Grant as of the 29th day of March, 2019.

NEKTAR THERAPEUTICS, Grantor

By: 
Name: Mark A. Wilson
Title: Senior Vice President and General Counsel

IN WITNESS WHEREOF, the undersigned have executed this Grant as of the ____ day of
March 29, 2019.

TC LENDING, LLC,
as Collateral Agent and Grantee

By:



Name: Robert (Bo) Stanley
Title: President

SCHEDULE A

Title	Serial No.	Filing Date
LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT	62/789,924	01/08/2019
POLYMER-DES-ETHYL SUNITINIB CONJUGATES	16/243,914	01/09/2019
CONJUGATES OF A FACTOR VIII MOIETY HAVING AN OXIME-CONTAINING LINKAGE	16/319,759	01/22/2019
OLIGOMER-FOSCARNET CONJUGATES	16/259,732	01/28/2019
CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY	16/266,718	02/04/2019
OLIGOMER-BETA BLOCKER CONJUGATES	16/277,785	02/15/2019
PARTICULATE MATERIALS	16/280,741	02/20/2019
LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT	62/818,003	03/13/2019
LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT	62/825,437	03/28/2019